A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...
The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...
Researchers have unveiled important new insights into how hormones known as androgens act on our cells - and the discovery could boost efforts to develop better treatments for prostate, ovarian and ...
Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy The 2022 AUA/ASTRO guidelines recommend 18-36 months of androgen deprivation therapy (ADT) ...
Researchers have created an epigenetic tool which has implications for medicine, sports, and agriculture. Researchers from the University of Otago -- Ōtākou Whakaihu Waka have created a world-first ...
Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer. Alicia Morgans, M.D., MPH: Androgen deprivation therapy, sometimes called ADT or hormonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results